Skip to Content
Merck

VEGFR3 is required for button junction formation in lymphatic vessels.

Cell reports (2023-07-16)
Melanie Jannaway, Drishya Iyer, Diandra M Mastrogiacomo, Kunyu Li, Derek C Sung, Ying Yang, Mark L Kahn, Joshua P Scallan
ABSTRACT

Lymphatic capillaries develop discontinuous cell-cell junctions that permit the absorption of large macromolecules, chylomicrons, and fluid from the interstitium. While excessive vascular endothelial growth factor 2 (VEGFR2) signaling can remodel and seal these junctions, whether and how VEGFR3 can alter lymphatic junctions remains incompletely understood. Here, we use lymphatic-specific Flt4 knockout mice to investigate VEGFR3 signaling in lymphatic junctions. We show that loss of Flt4 prevents specialized button junction formation in multiple tissues and impairs interstitial absorption. Knockdown of FLT4 in human lymphatic endothelial cells results in impaired NOTCH1 expression and activation, and overexpression of the NOTCH1 intracellular domain in Flt4 knockout vessels rescues the formation of button junctions and absorption of interstitial molecules. Together, our data reveal a requirement for VEGFR3 and NOTCH1 signaling in the development of button junctions during postnatal development and may hold clinical relevance to lymphatic diseases with impaired VEGFR3 signaling.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-NOTCH4 (Cleaved-Val1432), C-Terminal antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Tamoxifen, ≥99%